Consultant, Oncologie médicale, University College London Hospitals, UK
Spécialiste FMH en Hématologie
Spécialiste FMH en Médecine Interne
Spécialiste en Médecine interne, Hématologie et Oncologie médicale
Clinique de Genolier
Route du Muids 3
1272 Genolier
Consultant, Oncologie médicale, University College London Hospitals, UK
Médecin Chef, Oncologie médicale, EHC Morges Hospital, CH
Médecin Adjoint, Oncologie médicale, CHUV Lausanne, CH |
Médecin Associé, Oncologie médicale, IOSI-EOC, Ospedale Bellinzona, CH
Sarcoma Unit, The Royal Marsden Hospital London, UK |
Oncologie médicale, CHU Zürich, CH
Centre Pluridisciplinaire d’Oncologie (CePO), CHUV Lausanne, CH
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma.
Montemurro, M. et al. 2021 Feb;27(2):289-300
Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma. Dunet V, Halkic N, Sempoux C, Demartines N, Montemurro M, Prior JO, Schmidt S.; Eur Radiol. 2021 Feb;31(2):992-1001
LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma
Montemurro, M., et al. Cell Rep. 2020 Mar 31;30(13):4567-4583
Oncological outcome, functional results and costs after unplanned excision of musculoskeletal soft tissue sarcoma
Morattel , Mustaki, Montemurro, Letovanec, Durham, Becce, Omoumi, di Summa, Matter, Rüdiger , Cherix
Eur J Surg Oncol. 2020 May;46(5):898-904
Tumor response and outcome after reverse treatment for patients with synchronous colorectal liver metastasis ….
Du Pasquier C, Roulin D, Bize P, Sempoux C, Rebecchini C, Montemurro M, Schäfer M, Halkic N, Demartines N.
BMC Surg. 2020 Apr 19;20(1):78
Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer.
De Bari B, Franzetti-Pellanda A, Saidi A, Biggiogero M, Hahnloser D, Montemurro M, Bourhis J, Zeverino M, Ozsahin M. J Cancer Res Clin Oncol. 2019 Apr;145(4):1075-1084
Long-term outcome of dasatinib first-line treatment in GIST: A multicenter, 2-stage phase 2 trial (SAKK 56/07).
Montemurro M et al.; Cancer. 2018 Apr 1;124(7):1449-1454
Sarcoma of the heart: survival after surgery.
Niclauss L, Montemurro M, Kirsch M, Prêtre R.; Interact Cardiovasc Thorac Surg. 2018 Aug; 27(2):198-201
Radiation Therapy for GIST Progressing During Or After Tyrosine Kinase Inhibitor Therapy: A Prospective Study
Joensuu H, Eriksson M, Collan J, Balk M, Leyvraz S, Montemurro M; Radiother Oncol. 2015 Aug; 116(2):233-8
Survival after surgical drainage of malignant pericardial effusion
Niclauss L, Montemurro M, Prêtre R; World J Surg 2015 Jul;39(7):1767
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour …..
M. Montemurro et al.; European Journal of Cancer 2013 Mar;49(5):1027-31
Continuous Sunitinib treatment in patients with advanced HCC: a SAKK and SASL multicenter phase II trial (SAKK 77/06). Koeberle D, Montemurro M et al.; Oncologist. 2010;15(3):285-92.
Early prediction of response to sunitinib after imatinib failure by 18F-FDG-PET in patients with GIST
Prior JO, Montemurro M et al. ; J Clin Oncol. 2009 Jan 20;27(3):439-45. Epub 2008 Dec 8.
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Montemurro M et al.; Eur J Cancer. 2009 Sep;45(13):2293-7
PCNSL treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell
transplantation and response-adapted whole-brain radiotherapy: results of the multicenter OSHO-53 phase II study. Montemurro M et al.; Ann Oncol. 2007 Apr;18(4):665-71.
Chapitre de Livre
Principles of Tumor Therapy
In: “HEROLD – INNERE MEDIZIN”, Gerd Herold (editeur), Germany; since 2010, mis à jour annuelle
ESMO Examination Oncologie médicale |
Hématologie et Oncologie interne
Médecine interne
Thèse de recherche, Faculté de médecine, Université Essen, Allemagne |
Médecine, Johann Wolfgang Goethe Universität, Frankfurt, Allemagne